Behind the Bell: Castle Biosciences

In this episode of Behind the Bell, Castle Biosciences Founder & CEO Derek J. Maetzold shares the impact of CSTL being Nasdaq-listed on the company’s mission in developing innovative genomic tests.

Transcript: 

Have a plan, have an opportunity to succeed, knowing full well we're all going to stumble sometimes, so make sure you have a plan that lets you be able to pick yourself up and drive towards the ultimate goal.

The mission of Castle Biosciences is to focus on developing innovative genomic tests that improve the ability of clinicians and their patients to make better treatment decisions in the care of their cancers.

We launched Castle Biosciences with the IPO on Nasdaq in the middle of 2019, grew from three people in 2008 to 600 people today.

And to have an opportunity to come here and celebrate increasing awareness of melanoma and Castle Biosciences’ patients that we serve, clinicians that we help, and our employee base, is just fantastic.

Nasdaq represents to Castle the opportunity to really grow strong access capital markets for investors that actually care about life sciences, improving health care patients going forward and putting those two things together means that we're successful overall.